Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology (NASDAQ: KURA) and Kyowa Kirin announced that data from their KOMET-007 trial of ziftomenib will be presented at the 2025 European Hematology Association Congress in Milan. The presentation will focus on clinical data from combining ziftomenib, an oral menin inhibitor, with standard chemotherapy (7+3) in newly diagnosed NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) patients. The data comes from Phase 1a dose-escalation and Phase 1b dose-expansion portions of the trial. Two additional abstracts for the KOMET-001 and KOMET-017 trials will also be presented. Dr. Mollie Leoni, Chief Medical Officer of Kura Oncology, expressed confidence in ziftomenib's potential as a treatment option for AML patients when combined with intensive chemotherapy.

Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Bank of America Securities 2025 Healthcare Conference. The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a fireside chat on May 13, 2025, at 6:00 p.m. ET / 3:00 p.m. PT. Investors can access a live audio webcast of the presentation through Kura's website, with a replay available afterward.

Kura Oncology (NASDAQ: KURA) announced that its Compensation Committee granted inducement awards to 16 new employees on May 1, 2025. The awards consist of nonstatutory stock options to purchase 433,950 shares of common stock under the Company's 2023 Inducement Option Plan. The stock options have an exercise price of $6.49 per share, matching the company's closing price on May 1, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology (KURA) reported significant progress in Q1 2025, highlighted by the submission of its first NDA for ziftomenib to treat adult patients with relapsed/refractory NPM1-mutant AML. The company earned a $45 million milestone payment from Kyowa Kirin for the NDA submission. Q1 financial results showed collaboration revenue of $14.1M, with a net loss of $57.4M. The company maintains a strong financial position with $703.2 million in pro forma cash. Key upcoming milestones include data presentations at ASCO and EHA, initiation of two Phase 3 trials in frontline AML settings, and expansion of clinical programs. First patients were dosed in the KOMET-015 Phase 1 trial for GIST treatment. The company's cash runway extends into 2027 and is expected to support ziftomenib commercialization through frontline AML combination setting.

Kura Oncology (KURA) has initiated dosing in KOMET-015, a Phase 1 clinical trial evaluating ziftomenib in combination with imatinib for patients with advanced gastrointestinal stromal tumors (GIST) who failed imatinib treatment. The trial aims to assess safety, tolerability, and preliminary antitumor activity.

Preclinical studies showed the combination demonstrates robust antitumor activity in both imatinib-sensitive and resistant GIST models through a synthetic lethal mechanism. With 4,000-6,000 new GIST cases diagnosed annually in the U.S. and 60% of patients developing imatinib resistance within two years, ziftomenib could potentially delay or overcome this resistance.

The KOMET-015 Phase 1a/1b trial will evaluate safety, determine recommended Phase 2 dosing, and measure endpoints including clinical benefit, overall response rate, progression-free survival, and overall survival. This marks the first clinical trial combining a menin inhibitor with standard GIST treatments.

Kura Oncology (KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. market close on Thursday, May 1, 2025.

Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss financial performance and provide a corporate update. Investors can access the live call via phone using the numbers (800) 245-3047 (domestic) or (203) 518-9765 (international) with conference ID: KURAQ1. A live webcast and replay will be available through the investor relations section of Kura's website.

Kura Oncology (KURA) and Kyowa Kirin have submitted a New Drug Application (NDA) to the FDA for ziftomenib, their oral menin inhibitor designed to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation.

The submission was completed on March 31, 2025, with FDA expected to determine application completeness within 60 days. Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The company has requested Priority Review, which could result in a six-month FDA review period if granted.

This therapeutic candidate represents a potential first FDA-approved targeted therapy for NPM1-mutant AML patients, addressing an significant unmet medical need in this devastating disease.

Kura Oncology (NASDAQ: KURA) has announced the granting of inducement awards to four new employees as approved by the Company's Compensation Committee on April 1, 2025. The awards consist of nonstatutory stock options to purchase 79,500 shares of common stock under the Company's 2023 Inducement Option Plan.

The stock options have an exercise price of $6.38 per share, matching Kura's closing sales price on April 1, 2025. The vesting schedule spans four years, with 25% of shares vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.

Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum.

The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a virtual fireside chat scheduled for April 8, 2025, at 10:30 a.m. ET / 7:30 a.m. PT. Investors and interested parties can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.